LPCN Lipocine

Filed: 1 Nov 21, 8:00am












Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934


Date of Report (Date of Earliest Event Reported):

November 1, 2021





(Exact name of registrant as specified in its charter)


Commission File No. 001-36357


Delaware 99-0370688

(State or other jurisdiction

of incorporation)


(IRS Employer

Identification Number)


675 Arapeen Drive, Suite 202

Salt Lake City, Utah 84108

(Address of principal executive offices) (Zip Code)


Registrant’s telephone number, including area code: (801) 994-7383


Former name or former address, if changed since last report: Not Applicable




Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, par value $0.0001 per share LPCN The NASDAQ Stock Market LLC


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).


Emerging growth company


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐







Item 8.01Other Events


On November 1, 2021, the Company issued a press release announcing presentations at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021. The press release is filed as Exhibit 99.1 and is incorporated herein by reference.


Additionally, the Company is presenting data at The Liver Meeting® 2021 on November 12-15, 2021. The Company’s materials to be included are filed as Exhibits 99.2, 99.3 and 99.4.


Item 9.01Financial Statements and Exhibits.


(d) Exhibits


The following exhibits are filed with this report:


Exhibit No. Description




Press Release announcing Multiple Poster Presentations at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021

99.2 Abstract entitled “LPCN 1144 Therapy Demonstrates Histologic Benefits In The Phase 2 LiFT Study in Non-Alcoholic Steatohepatitis (NASH) Subjects”
99.3 Abstract entitled “Safety And Tolerability Of LPCN 1144 Treatment In Biopsy Confirmed NASH Subjects In The Phase 2 LiFT Study”
99.4 Abstract entitled “LPCN 1144 Improves Body Composition In Biopsy-Confirmed NASH Patients”
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date:November 1, 2021By:/s/ Mahesh V. Patel
   Mahesh V. Patel
   President and Chief Executive Officer